PU Shanyu, PAN Yuesong, WANG Yongjun. Interpretation of INSURE Study: the Application Value of Indobufen in Stroke[J]. Chinese Journal of Stroke, 2023, 18(06): 633-635.
[1]PAN Y S,MENG X,YUAN B S,et al. Indobufen versus aspirin in patients with acute ischaemic stroke in China(INSURE):a randomised,double-blind,double-dummy,active control,non-inferiority trial[J]. Lancet Neurol,2023,22(6):485-493.
[2]杨霞,刘维,陈恳,等. 吲哚布芬片预防和治疗缺血性心脑血管病变有效性和安全性的Meta分析[J]. 中国临床药理学杂志,2017,33(4):359-362.
[3]WU H Y,XU L L,ZHAO X,et al. Indobufen or
aspirin on top of clopidogrel after coronary drug-eluting stent implantation(OPTION):a randomized,open-label,end point-blinded,noninferiority trial[J]. Circulation,2023,147(3):212-222.
[4]HANKEY G J,EIKELBOOM J W. Aspirin resistance[J]. Lancet,2006,367(9510):606-617.
[5]LATIB A,IELASI A,FERRI L,et al. Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation:a proposed alternative regimen[J]. Int J Cardiol,2013,165(3):444-447.
[6]MATSUMOTO M. Cilostazol in secondary prevention of stroke:impact of the cilostazol stroke prevention study[J]. Atheroscler Suppl,2005,6(4):33-40.
[7]HUANG Y N,CHENG Y,WU J,et al. Cilostazol as an alternative to aspirin after ischaemic stroke:a randomised,double-blind,pilot study[J]. Lancet Neurol,2008,7(6):494-499.
[8]WANG Y L,ZHAO X Q,LIN J X,et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack[J]. JAMA,2016,316(1):70-78.
[9]PAN Y S,CHEN W Q,XU Y,et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack:a systematic review and meta-analysis[J]. Circulation,2017,135(1):21-33.
[10]GEORGE B P,FALCONE G J. One step closer to precision medicine strategies based on genetic information:ABCB1 polymorphisms in the CHANCE trial[J]. JAMA Neurol,2019,76(5):523-525.
[11]COLE J W. F2R polymorphisms and clopidogrel efficacy and safety:another step toward precision medicine[J]. Neurology,2021,96(1):10-11.
[12]中国医师协会心血管内科医师分会,中国卒中学会. 常用口服抗血小板药物不耐受及低反应性人群诊疗专家共识[J]. 中国介入心脏病学杂志,2021,29(5):240-249.